Open AccessEfficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study
Author(s) -
Qiuxia Zhong,
Zhihua Liu
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
ISSN - 1179-1322
DOI - 10.2147/cmar.s304838
Subject(s) - medicine , oncology , lung cancer , univariate analysis , proportional hazards model , progression free survival , retrospective cohort study , epidermal growth factor receptor , clinical endpoint , tyrosine kinase inhibitor , multivariate analysis , cancer , overall survival , clinical trial
Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) independently developed by China, which can inhibit tumor angiogenesis and tumor cell proliferation. The ALTER 0303 study has suggested that anlotinib improved overall survival (OS) and progression-free survival (PFS) in the treatment of advanced non-small cell lung cancer (NSCLC). However, in the real world, the efficacy and safety of anlotinib is not clear. Although relevant retrospective studies have confirmed the efficacy and safety of anlotinib, the sample size is small. And the OS was not observed because of the follow-up time was short. Further studies are still essential to evaluate the efficacy and safety of anlotinib in patients with advanced NSCLC in real-world settings. Related studies have preliminarily shown that anlotinib combined with whole-brain radiotherapy (WBRT) can significantly prolong the survival of patients with brain metastases of NSCLC. This study also discusses the best treatment strategies of patients with brain metastases.